Maintenance therapy for advanced lung cancer: Who, what, and when?

Journal of Clinical Oncology

Volumn 31, Issue 24, 2013, Pages 2983-2990

  Gerber, David E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; THYROID TRANSCRIPTION FACTOR 1; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; DYSLIPIDEMIA; ENDOBRONCHIAL ULTRASONOGRAPHY; FEMALE; GENE MUTATION; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG NODULE; LYMPHADENOPATHY; MAINTENANCE THERAPY; MEDIASTINUM DISEASE; MEDIASTINUM LYMPH NODE; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RIGHT LUNG; SMOKING; SPLEEN TUMOR; THORAX RADIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TUMOR DIFFERENTIATION; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE;

EID: 84887229536     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.5201     Document Type: Article

References (43)

1. Earle CC, Venditti LN, Neumann PJ, et al: Who gets chemotherapy for metastatic lung cancer? Chest 117:1239-1246, 2000
2. Rasco DW, Yan J, Xie Y, et al: Looking beyond surveillance, epidemiology, and end results: Patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 5:1529-1535, 2010
3. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
4. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006
5. Socinski MA, Schell MJ, Peterman A, et al: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by secondline therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335-1343, 2002
6. Belani CP, Barstis J, Perry MC, et al: Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21:2933-2939, 2003
7. Belani CP, Waterhouse DM, Ghazal H, et al: Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabinecarboplatin (G-Cb) for patients with advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol 28: 540s, 2010 (suppl; abstr 7506)
8. Westeel V, Quoix E, Moro-Sibilot D, et al: Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 97:499-506, 2005
9. Brodowicz T, Krzakowski M, Zwitter M, et al: Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 52:155-163, 2006
10. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
11. Barlesi F, Scherpereel A, Rittmeyer A, et al: Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31:3004-3011, 2013
12. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374:1432-1440, 2009
13. Paz-Ares L, de Marinis F, Dediu M, et al: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247-255, 2012
14. Paz-Ares L, De Marinis F, Dediu M, et al: PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 30:481s, 2012 (suppl; abstr LBA7507)
15. Patel JD, Bonomi P, Socinski MA, et al: Treatment rationale and study design for the pointbreak study: A randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/ carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 10:252-256, 2009
16. Patel JD, Socinski MA, Garon EB, et al: A randomized, open-label, phase 3, superiority study of pemetrexed (Pem) + carboplatin (Cb) + bevacizumab (B) followed by maintenance Pem + B versus paclitaxel (Pac) + Cb + B followed by maintenance B in patients (pts) with stage IIIB or IV non-squamous non-small cell lung cancer (NSNSCLC). J Thorac Oncol 7:S336-S338, 2012
17. Zinner RG, Saxman SB, Peng G, et al: Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology. Clin Lung Cancer 11:352-357, 2010
18. Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:591-598, 2009
19. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
20. Pérol M, Chouaid C, Pérol D, et al: Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatingemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30:3516-3524, 2012
21. Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531, 2009
22. Lopez-Chavez A, Young T, Fages S, et al: Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the eastern cooperative oncology group 4599 study: Results of an exploratory analysis. J Thorac Oncol 7:1707-1712, 2012
23. Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473-2483, 2011
24. Klein R, Wielage R, Muehlenbein C, et al: Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous nonsmall cell lung cancer. J Thorac Oncol 5:1263-1272, 2010
25. Lee CP, Chertow GM, Zenios SA: An empiric estimate of the value of life: Updating the renal dialysis cost-effectiveness standard. Value Health 12:80-87, 2009
26. Gerber DE, Rasco DW, Le P, et al: Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: Real-world considerations for maintenance therapy. J Thorac Oncol 6:365-371, 2011
27. Sun JM, Park JO, Won YW, et al: Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy. J Thorac Oncol 5:540-545, 2010
28. Somer RA, Sherman E, Langer CJ: Restrictive eligibility limits access to newer therapies in nonsmall-cell lung cancer: The implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer 9:102-105, 2008
29. Cenik BK, Sun H, Gerber DE: The impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. Lung Cancer 80:326-332, 2013
30. Ardizzoni A, Boni L, Tiseo M, et al: Cisplatinversus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 99:847-857, 2007
31. Azzoli CG, Kris MG, Pfister DG: Cisplatin versus carboplatin for patients with metastatic nonsmall-cell lung cancer: An old rivalry renewed. J Natl Cancer Inst 99:828-829, 2007
32. Gerber DE, Hamann HA, Rasco DW, et al: Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer. Patient Educ Couns 89:102-108, 2012
33. Silvestri G, Pritchard R, Welch HG: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. BMJ 317:771-775, 1998
34. Peeters L, Sibille A, Anrys B, et al: Maintenance therapy for advanced non-small-cell lung cancer: A pilot study on patients' perceptions. J Thorac Oncol 7:1291-1295, 2012
35. Gridelli C, Bennouna J, de Castro J, et al: Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-smallcell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: Treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer 12:407-411, 2011
36. Bennouna J, Sastre J, Arnold D, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 14:29-37, 2013
37. Taylor CD, Elson P, Trump DL: Importance of continued testicular suppression in hormonerefractory prostate cancer. J Clin Oncol 11:2167-2172, 1993
38. von Minckwitz G, du Bois A, Schmidt M, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27: 1999-2006, 2009
39. Calais da Silva FE, Bono AV, Whelan P, et al: Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 55:1269-1277, 2009
40. Giuliani F, De Vita F, Colucci G, et al: Maintenance therapy in colon cancer. Cancer Treat Rev 36:S42-S45, 2010 (suppl 3)
41. Maughan TS, James RD, Kerr DJ, et al: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial. Lancet 361: 457-464, 2003
42. Riely GJ, Kris MG, Zhao B, et al: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150-5155, 2007
43. Yoshimoto A, Inuzuka K, Kita T, et al: Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am J Med Sci 333:221-225, 2007